Arvinas, Inc.

Arvinas, Inc.

ARVNNYSE / NASDAQHealthcareSmall cap

$6.46-$0.28 (-4.2%)

Last close · Data as of Nov 20, 2026

Market cap
$499.4M
P/E
-6.2x
EV / EBITDA
-3.2x
Revenue
$262.6M
Net margin
-30.8%
ROCE
-20.6%

-41.4% over the last year

Arvinas, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-15.7%
3M
-28.5%
6M
-29.0%
1Y
-41.4%
5Y
Hidden
  • This period includes a one-day price step on 11 Mar 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.28 (-4.2%) from $6.74 to $6.46 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ARVN, bought on each weekday since 2021.

News & filings

What Arvinas filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 80.8 million US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.02.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Read moreShow less

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Sector
Healthcare
Shares outstanding
63.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$499.4M
P/E
-6.2x
P/B
1.2x
EV / EBITDA
-3.2x
EV / Sales
1.4x
P/S
1.9x
52-week high
$13.83
52-week low
$6.41

Profitability

Operating margin
-45.1%
Net margin
-30.8%
EBITDA margin
-43.1%
ROE
-18.6%
ROCE
-20.6%
ROIC
-31.2%
ROA
-11.3%
Asset turnover
0.37

Growth

Revenue
$262.6M
Revenue growth, 1Y
-0.3%
Revenue CAGR, 3Y
26.0%
Net profit growth, 1Y
-59.4%
Free cash flow
-$275.7M

Solvency

Current ratio
4.92
Debt / Equity
0.02
Debt / Assets
0.01
CFO / Net profit
3.39
Cash / Market cap
28.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$262.6M
Gross profit$262.6M
Operating expenses$381.1M
Research and development$285.2M
Selling, general and administrative$95.9M
Operating income-$118.5M
Interest and other$38.0M
Pretax income-$80.5M
Tax and other$300.0k
Net income-$80.8M

Revenue and net profit

Revenue fell 0.3% in FY2025; net profit is the dashed line.

Arvinas, Inc. revenue and net profit by fiscal year
Arvinas, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$131.4M-$282.5M
FY2023$78.5M-$367.3M
FY2024$263.4M-$198.9M
FY2025$262.6M-$80.8M

Cash flows

FY2025: -$273.8M from operations, -$275.7M free after investment (dashed).

Arvinas, Inc. operating and free cash flow by fiscal year
Arvinas, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$273.5M-$280.3M
FY2023-$347.8M-$350.7M
FY2024-$259.3M-$261.1M
FY2025-$273.8M-$275.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$262.6M-0.3%1Y
EBITDA
-$113.3M
Net profit
-$80.8M
Cash from operations
-$273.8M
Free cash flow
-$275.7M
Revenue CAGR, 3Y
26.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$262.6M-$113.3M-$80.8M-$275.7M-18.6%-0.3%-59.4%

Monthly returns

Month-by-month returns of ARVN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$717.9M
Liabilities$284.1M
Equity$433.8M
Paid-in capital$2.1B
Retained earnings-$1.6B
Treasury stock$91.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ARVN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Arvinas, Inc.ARVNthis company$499.4M-6.2x1.2x-18.6%-3.2x
4D Molecular Therapeutics, Inc.FDMT$523.3M-3.7x1.0x-27.7%-3.2x
Aquestive Therapeutics, Inc.AQST$519.4M-6.2x-15.4x248.9%-6.7x
Pacific Biosciences of California, Inc.PACB$506.3M-0.9x94.6x-10214.5%-7.5x
AngioDynamics, Inc.ANGO$497.1M-14.6x2.7x-18.6%256.3x
Standard BioTools Inc.LAB$495.8M-6.6x1.2x-17.7%-4.7x
Evolent Health, Inc.EVH$492.7M-0.9x1.2x-128.7%-3.7x
Prothena Corporation plcPRTA$484.3M-2.0x1.7x-87.0%-1.0x
The Oncology Institute, Inc.TOI$473.9M-7.8x-30.1x385.5%-12.8x
Peer median—-5.0x1.2x-23.1%-4.2x

Year-to-date ROI

ARVN since 1 January, against earlier years.

Historical volatility

ARVN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Arvinas, Inc. operating margin by fiscal year
Arvinas, Inc. operating margin by fiscal year
DateOperating margin
FY2022-200.3%
FY2023-511.5%
FY2024-95.0%
FY2025-45.1%
LineFY2025
Operating expensesOperating Expense$381.1M
Research and developmentResearch And Development$285.2M
Total expensesTotal Expenses$381.1M
Pretax incomePretax Income-$80.5M

Learn while you research

Academy chapters picked for Arvinas, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →